Clinical trials: Middle Cerebral Artery Infarction
Middle Cerebral Artery Stroke
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT).
- Trial name
- NCT00401310
- Testing
- Comparator: MK0724
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic…
- Trial name
- NCT02928393
- Testing
- Basmisanil
- Where
- 13 sites in France, Spain
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Acute Ischaemic Middle Cerebral Artery Stroke
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their…
- Trial name
- NCT01883011
- Testing
- Piracetam
- Where
- 44 sites in Argentina, Austria and 13 more
- Volunteers
- 571 people
- Sponsor
- UCB S.A. - Pharma Sector
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Stroke, Ischemic, Infarction, Middle Cerebral Artery
Testing of Identification Markers for Stroke
Stroke is the third leading cause of death and the first cause of physical disability and dementia worldwide. Ischemic stroke caused by large vessel occlusion (LVO) is responsible for the vast majority of deaths and disabilities.
- Conditions
- Stroke, Ischemic, Infarction, Middle Cerebral Artery, Infarction, Anterior Circulation, Brain
- Trial name
- TIME (NCT04292600)
- Testing
- POCKiT diagnostics' algorithm for LVO detection
- Where
- 3 sites in United States
- Volunteers
- 383 people
- Sponsor
- POCKiT diagnostics Ltd
Infarction, Anterior Cerebral Artery, Infarction, Middle Cerebral Artery
An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam
Ischemic stroke occurs when an artery to the brain is blocked. If the artery remains blocked for more than a few minutes, the brain cells may die. This is why immediate medical treatment is critical.
- Conditions
- Infarction, Anterior Cerebral Artery, Infarction, Middle Cerebral Artery, Ischemic Attack, Transient
- Trial name
- NCT03679364
- Where
- 3 sites in Vietnam
- Volunteers
- 364 people
- Sponsor
- KPC Pharmaceuticals, Inc
Stroke, Acute, Middle Cerebral Artery Stroke
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following…
- Conditions
- Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
- Trial name
- NCT01310114
- Testing
- Human Placenta-Derived Cells PDA001- (cenplacel-L)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Celularity Incorporated